The inspection has been concluded with zero observations.
Third Quarter Results
Torrent Pharmaceuticals reported a net profit of ₹635 crore in Q3 FY26, up 26.3% from ₹503 crore in the same period last year. The company’s revenue grew 17.6% to ₹3,303 crore versus ₹2,809 crore in Q3 FY25. EBITDA increased 19% to ₹1,088 crore from ₹914 crore in the year-ago period. The EBITDA margin stood at 32.9%, slightly up from 32.5% in Q3 FY25.Also Read: Torrent Pharma shares gain 4% after steady Q3; Street positive on JB merger benefits
Revenue in India for Q3 FY26 was ₹1,798 crore, up 14% year-on-year. According to AIOCD PharmaTrac secondary market data, the Indian Pharmaceutical Market (IPM) grew 10% during the quarter. Torrent Pharma outperformed the market in chronic and sub-chronic therapies, led by the cardiac, gastro, and diabetes (OAD) segments. For 9M FY26, India revenues stood at ₹5,430 crore, up 12% from the same period last year.
Torrent’s Brazil revenues reached ₹371 crore, up 27% year-on-year. On a constant currency basis, revenues were R$224 million, up 10%. As per IQVIA data, Torrent grew 13% versus market growth of 7%, driven by top brands and recent launches. The company currently has 60 products under ANVISA review. For 9M FY26, Brazil revenues were ₹907 crore, up 21% (constant currency: R$564 million, up 13%).
The US business posted revenues of ₹321 crore, up 19% from the prior year. Constant currency revenues were $36 million, up 12%. Recent product launches in the US achieved their target market shares. For 9M FY26, US revenues were ₹967 crore (constant currency: $111 million, up 16%).
Also Read: Torrent Pharma shares surge 5% on JPMorgan upgrade; check revised price target
Shares of Torrent Pharmaceuticals Ltd ended at ₹4,165.80, up by ₹72.65, or 1.77%, on the BSE.
(Edited by : Jomy Jos Pullokaran)
First Published: Apr 10, 2026 7:22 PM IST
